Imbria Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.imbria.com
Clinical Trials
11
Active:4
Completed:5
Trial Phases
2 Phases
Phase 1:4
Phase 2:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (55.6%)Phase 1
4 (44.4%)A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Phase 2
Not yet recruiting
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Ninerafaxstat 200mg MRDrug: Placebo
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Imbria Pharmaceuticals, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT07023614
Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)
Phase 2
Completed
- Conditions
- IschemiaCoronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Imbria Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04826172
- Locations
- 🇸🇪
Imbria Investigational Site, Uppsala, Sweden
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
Phase 2
Completed
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Imbria Pharmaceuticals, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT04826185
- Locations
- 🇬🇧
Imbria Investigational Site, Oxford, United Kingdom
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
Phase 2
Completed
- Conditions
- Diabetic CardiomyopathiesType 2 DiabetesHFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Imbria Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04826159
- Locations
- 🇬🇧
Oxford University Hospital, Oxford, United Kingdom
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Imbria Pharmaceuticals, Inc.
- Target Recruit Count
- 640
- Registration Number
- NCT04306237
- Locations
- 🇺🇸
Imbria Investigational Site, Boston, Massachusetts, United States
News
No news found